Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab combinations versus pembrolizumab monotherapy in first-line PD-L1-high advanced non-small cell lung cancer
2017-001041-27Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cemiplimab, ipilimumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Mar 2018; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001041-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001041-27.